Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.

about

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.

Item

http://www.wikidata.org/entity/Q48177244

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.

@en

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.

@nl

type

Item

label

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.

@en

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.

@nl

prefLabel

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.

@en

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.

@nl

P1476

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

@en

P2093

Guoqiang Dong

http://www.w3.org/2001/XMLSchema#string

Hongyu Wang

http://www.w3.org/2001/XMLSchema#string

Kun Fang

http://www.w3.org/2001/XMLSchema#string

Shanchao Wu

http://www.w3.org/2001/XMLSchema#string

Shipeng He

http://www.w3.org/2001/XMLSchema#string

Wei Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Human tumor antigens recognized by T lymphocytes

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

Research progress of indoleamine 2,3-dioxygenase inhibitors

The future of immune checkpoint therapy

T cell exclusion, immune privilege, and the tumor microenvironment

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

P304

30-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CMDC.201700666

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chunquan Sheng

P577

2017-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29205945

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy